EP-1374: Contouring guideline optimisation for prostate pts undergoing carbon ions/photons combined treatment  by Giandini, T. et al.
ESTRO 35 2016                                                                                                                                                    S641 
________________________________________________________________________________ 
patients (7%) died: 2 of disease progression and 2 of other 
causes. Mean and median time-to-progression are 12.1 and 
9.8 months respectively (range 2-53). 
 
Conclusion: Re-EBRT using stereotactic approach is a feasible 
option for local prostate cancer recurrence, achieving tumour 
control in 45% of the patients and an acceptable progression-
free interval. Toxicity of re-EBRT appeared to be very low. 
Future studies are needed to identify those patients who 
would benefit the most from this treatment. 
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Purpose or Objective: to evaluate the outcomes in 
intermediate risk prostate cancer treated with 
hypofractionated radiotherapy (HyRT) 
 
Material and Methods: Between March 2007 and March 2015, 
145 patients affected by intermediate risk (T2b–T2c prostate 
cancer or Gleason Score equal to 7 or pre-treatment PSA 
value ranging from 10 to 20 ng/mL) prostate cancer were 
treated with HyRT. The median age at diagnosis was 74 years 
(range 53-88). A pre-treatment CT scan with 2.5 mm slices 
was obtained. MRI was used to better delineate the Clinical 
Target Volume (CTV) when available. The CTV1 included the 
prostate plus seminal vesicles (SSVV) and the CTV2 the 
prostate alone. Planning Target Volumes (PTV1 and PTV2, 
respectively) were generated with 8 mm margin in all 
directions except posteriorly where a 6 mm expansion was 
adopted in the first 36 patients. A 5 mm expansion in all 
direction was used in the other patients as daily kv Cone 
Beam CT was used to verify the patient position because of 
an implementation of the linear accelerator. A 3D-CRT and a 
15 MV photons linear accelerator was used to deliver the 
treatment. The PTV1 received 43.8 Gy in 12 fractions and the 
PTV2 received 54.75 Gy in 15 fractions, three times a week in 
order to avoid an excess of acute toxicity. Neoadjuvant, 
concomitant and adjuvant ADT was administered for a total 
of 9 months and was started 3 months before RT. 
 
Results: After a median follow-up of 52.4 months (range 7 to 
95 months), 11 patients (7.6%) died, of whom 9 for 
intercurrent disease and 2 (1.3%) for PCa. The 5-year OS was 
90.1% (95%CI 84.2-97.6%) and the 5-year CSS was 98.6% 
(95%CI 95.4-100%). Fourteen patients (9.7%) developed 
biochemical recurrence after a median follow up of 30.5 
months (95% CI 28.5 to 32.5 months). Of these patients, 
thirteen (9.0%) had also a clinical detectable disease while 
the remaining patient presented only biochemical 
recurrence. The 5y-bRFS was 88.8% (95%CI 82.8-95.4%). 
Among the 13 patients with clinical recurrence, 7 (53.8%) had 
local recurrence, 2 (15.4%) developed distant metastases, 
and 4 (30.8%) had both local recurrence and distant 
metastases. Acute genito-urinary (GU) toxicity of grade 1 
occurred in 74 patients (51.0%), grade 2 in 15 patients 
(10.3%) and grade 3 in 2 patients (1.3%). Acute gastro-
intestinal (GI) toxicity of grade 1 were observed in 27 
patients (18.6%), grade 2 in 12 patients (8.2%). None 
developed acute GI toxicity of grade 3 or 4. Late GU toxicity 
occurred as follows: grade 1 in 51 patients (35.2%), grade 2 in 
12 patients (8.2%), grade 3 in 2 patients (1.3%). Late GI 
toxicity of grade 1 was observed in 18 patients (12.4%), grade 
2 in 6 patients (4.1%) and grade 3 in 1 patient (0.7%). 
 
Conclusion: The hypofractionated schedule used is well 
tolerated with a low rate of acute and late grade ≥ 2 
gastrointestinal and genitourinary toxicities. 
Hypofractionation is useful to obtain high rate of tumor 
control but a longer follow-up is needed for definitive 
conclusion. 
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Purpose or Objective: In the context of the multi-
institutional research project “Carbon ions boost followed by 
pelvic photon intensity modulated radiotherapy for high risk 
prostate cancer”, Contouring Guidelines (CG) for target 
volumes and Organs At Risk (OARs) were commonly defined 
based on National/International standards and local 
experiences. Intra- and inter-institutional variability was 
evaluated within a contouring dummy-run and a graphical 
tool was developed to assist the Radiation Oncologists (ROs) 
in the standardization of the contouring. 
 
Material and Methods: CT and MR images of 5 prostate 
patients were randomly chosen. Seven ROs belonging to the 
three Institutes involved in the project were assigned to 
independently contour targets (prostate (GTV-P), seminal 
vesicles (CTV-VS) and pelvic lymph nodes (CTV-N) and OARs 
(rectum (R), bladder (B), femoral heads (FH), small bowel 
(SB) , penile bulb (PB) and anal canal (AC). The registration 
between CT and MR images was only used to contour GTV-P 
and PB. The contours were compared by means of the DICE 
Index (defined as 2*(A∩B)/(A+B), where A e B are the 
volumes in comparison), as provided by the commercial 
software VODCA (MSS, v.5.4.0). For each structure, the 
Global DICE Index (GDI) was calculated as the average value 
for all the ROs and the patients and then compared with the 
DICE Index of the individual ROs: an individual DICE Index 
lower than the corresponding GDI (or lower than a threshold 
value of 0.9 for GDI > 0.9) was recorded as “disagreement” 
and reported in a graphical tool (Figure 1) that qualitatively 
shows intra- and inter-institutional variability. 
 
Results: The resulting GDI are reported in Table 1. A visual 
analysis of the contours on the CT images showed that the 
poor quality GDI for CTV-VS and AC were due both to a not 
strict application of the CG by the ROs of the different 
Institutes and to the small volume of those structures. The 
other results were instead attributable to random variation in 
the contouring. The graphical tool clearly showed that inter-
institutional variability was predominant compared to intra-
institutional variability both for targets and OARs. 
Nevertheless, some disagreement was found even between 
ROs of the same Institute. 
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Conclusion: The dummy-run showed that the most significant 
deviations were obtained when ROs did not precisely apply 
the CG. Such systematic deviations in the contouring could 
have a dosimetric impact both for target coverage and OAR 
sparing, especially for particle therapy. The ROs were 
provided with the developed graphical tool in order to easily 
identify their deviations and take corrective actions. The 
graphical tool could also be useful for the optimization of the 
contouring strategies within individual Institutes. 
This work was partially funded by Associazione Italiana per la 
Ricerca sul Cancro AIRC (grant N-14300) 
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Purpose or Objective: To evaluate the role of adjuvant 
androgen deprivation therapy (ADT) in combination with 
postoperative radiotherapy (PORT) on biochemical-relapse-
free-survival (b-NED) and metastatic-progression-free-survival 
(mts-NED) in high risk prostate cancer patients (pts). 
 
Material and Methods: Between 2004 and 2012 370 high risk 
prostate cancer pts received PORT : 120 pts had stage pT3a 
pN0, 150 pts pT3b pN0 , 100 pts pT2c/pT3 R1 and post 
surgical PSA > 0.2 ng/ml detected in 50 pts. Mean age was 72 
years (55-78 yrs). PORT on pelvis and surgical bed was 
delivered in 150 pts while 220 pts were treated on surgical 
bed . Dose to pelvis was 45-50 Gy, while dose on surgical bed 
was 66- 72 Gy. ADT was administerd in 250 pts and consisted 
of LH-RH analog in monotherapy (70 pts), BAT (60 pts) and 
bicalutamide 150 mg (120 pts). Timing of ADT ranged six 
months to 3 years. ADT was administered during and after 
PORT with a median of 35 months. Kaplan-Mayer b-Ned and 
mts-Ned survivals , X-square (p< 0.05) and paired t-test for 
univariate and multivariate analyses (p< 0.001) were 
calculated.  
 
Results: Three – hundred were evaluable at 64 months with a 
median of 5 years. Two groups were identified: ADT (210 pts) 
and no ADT (90 pts). One-hundred and twenty pts (120) 
relapsed: 40 pts in the no ADT group (5 with a biochemical 
relapse and 35 pts with a metastatic relapse) and 70 pts in 
the ADT group (20 pts with a biochemical relapse and 50 pts 
with a metastatic). The 5- year biochemical relapse free 
survival was 80% for ADT group and 78% for no ADT group (p = 
0.34); the 5-year metastatatic progression free survival for 
ADT group was 82 % vs 65% (p< 0.05)for no ADT group. In the 
ADT group, radiotherapy dose <70 Gy and PSA >0.2 ng/ml 
were indipendent factors related to high risk of biochemical-
relapse while metastatic-relapse-free-survival was influenced 
by primary component 5 of the Gleason Score (GS) , no use of 
LH-RH analog and time of ADT<2aa . In the no ADT group, PSA 
> 0.2 ng/ml, radiotherapy dose <70 Gy and R1 disease, were 
factors influencing the biochemical relapse, while 
metastastic relapse was influenced by a value of 5 in the 
Gleason Score. 
 
Conclusion: The role of ADT in adjuvant setting prostate 
cancer is still unclear; our results suggest a benefit of ADT in 
metastatic-progression-free-survival, especially in case of 
primary component 5 in the GS , post-operative PSA >0, 
BAT<2 years. 
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Purpose or Objective: This study reports long-term patient 
reported urinary function, toxicity and related quality of life 
(QoL) after external beam radiotherapy for localized prostate 
cancer. 
 
Material and Methods: 574 men underwent definitive 3D 
conformal radiotherapy to 74Gy ± androgen deprivation 
therapy between 2000 and 2009 with a median follow-up of 
42 months. Patients were evaluated at baseline and post 
treatment using the International Prostate Symptom Score 
(IPSS) and RTOG CTC. 
 
Results: For patients with mild (48%), moderate (40%) and 
severe (12%) baseline total IPSS, median IPSS at baseline was 
3,12, and 24. Median IPSS was 4, 9, and 12 at 6 months and 3, 
9 and 14 at 48 months respectively. Late grade 2 
genitourinary toxicity incidence was 7%, 20% and 33% and late 
grade 3 genitourinary toxicity was 1%, 2% and 1% 
respectively. At 48 months, 80%, 49% and 16% of patient with 
baseline mild, moderate and severe IPSS respectively 
demonstrated stable IPSS, 5%, 39% and 72% reported 
improving IPSS ≥5, and 14%, 12% and 6% had a worsening IPSS 
≥5. 82% of patients with mild baseline IPSS had mild IPSS 
scores. 95% of patients with moderate baseline IPSS had mild 
or moderate IPSS scores, with 43% improving to mild IPSS 
scores. 75% of patients with severe baseline IPSS scores had 
improved to mild (28%) or moderate (47%) IPSS scores. 68% of 
the cohort reported good baseline urinary QoL (score 0-2), 
with 89% of these patients maintaining good urinary QoL at 48 
months. 71% of patients with poor baseline urinary QoL (score 
3-6) had improved to good urinary QoL. 
 
 
 
Conclusion: The majority of men undergoing definitive 
radiotherapy for prostate cancer report stable or improving 
late urinary symptom burden and urinary quality of life, even 
with severe urinary symptoms or poor urinary quality of life 
at baseline. 
 
 
 
 
